The discussion highlighted the company's strategic move into pharmaceuticals with NB4168, a promising NAD analog for rare diseases and aging, supported by a world-class scientific team. Fiscal discipline and steady growth in core businesses remain priorities.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.